NIKKEI 225
29,346.91-821.36(-2.72%)HANG SENG
29,342.49-731.68(-2.43%)CRUDE OIL
63.16-0.37(-0.58%)
BioNTech SE (BNTX)
109.00 -3.33 (-2.96%)
After hours: 7:59PM EST
| Previous close | 114.17 |
| Open | 114.87 |
| Bid | 108.80 x 900 |
| Ask | 112.69 x 800 |
| Day's range | 111.18 - 117.30 |
| 52-week range | 28.00 - 131.00 |
| Volume | 1,129,800 |
| Avg. volume | 3,318,958 |
| Market cap | 27.047B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 10 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 120.44 |
- Reuters
Pfizer-BioNTech testing booster of their COVID-19 vaccine in new trial
Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. They are also in talks with regulatory authorities about testing a vaccine modified to protect specifically against the highly transmissible new variant found in South Africa and elsewhere, known as B.1.351, as a second arm of the same study. The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere.
- Business Wire
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the opportunity to receive a 30 µg booster of the current vaccine 6 to 12 months after receiving their initial two-dose regimen. The study is part of the Companies’ clinical development strategy to determine the effectiveness of a third dose against evolving variants.
- Yahoo Finance
Moderna expands vaccine production, sets 2022 target of 1.4B doses
Moderna announces new expansion plans, and a study for its booster shot that targets the South African variant.
